Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $155 to $200.